SCHEDULE: Key Investor Vedanta Associates Reduces Stake in Reviva Pharmaceuticals Below 5%
Beneficial Ownership Update
An amended Schedule 13D filing reveals that Vedanta Associates, L.P. has reduced its beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. to below the 5% threshold, while other affiliated entities and individuals maintain significant stakes.
Summary
- Vedanta Associates, L.P. now beneficially owns 3,408,401 shares of Reviva Pharmaceuticals Holdings, Inc. Common Stock, representing 4.8% of the outstanding shares as of July 1, 2025.
- Vedanta Partners, LLC beneficially owns 5,367,069 shares, equating to 7.5% of the outstanding Common Stock.
- Parag Saxena, an individual reporting person, beneficially owns 6,259,806 shares, representing 8.7% of the outstanding Common Stock.
- The percentages are based on 68,003,613 outstanding shares of Common Stock as of July 1, 2025.
- Vedanta Associates ceased to be a beneficial holder of more than five percent of the Issuer's Common Stock on June 27, 2025.
- The beneficial ownership includes shares held directly, as well as shares underlying warrants and pre-funded warrants held by various affiliated entities (Beta Operators Fund, L.P., Vedanta R2 Partners, LP, Vedanta Associates-R, L.P.).
- Parag Saxena's beneficial ownership also includes 21,400 shares underlying fully vested options as of the filing date.
- No transactions in the Issuer's securities were effected by the Reporting Persons during the sixty days prior to the filing date.
Sentiment
Score: 5
Explanation: The document is a factual update on beneficial ownership, with no explicit positive or negative financial results. The reduction in stake by one reporting entity is a factual change in ownership structure.
Negatives
- Vedanta Associates, L.P. reduced its beneficial ownership to below 5% of the outstanding Common Stock, indicating a decrease in a significant investor's reportable stake.
Future Outlook
No forward-looking statements or guidance are provided in this beneficial ownership filing.
Industry Context
This filing is a routine disclosure of changes in significant beneficial ownership, common across all publicly traded sectors. It does not provide specific insights into broader industry trends or competitive landscape beyond the ownership structure of Reviva Pharmaceuticals.
Related Party Transactions
- The reporting persons (Parag Saxena, Vedanta Partners, LLC, and Vedanta Associates, L.P.) are affiliated entities and individuals, and their reported holdings represent their collective and individual beneficial ownership in the Issuer.
Stakeholder Impact
- Shareholders: The change in beneficial ownership by a significant investor may influence market perception and trading activity, particularly for Vedanta Associates reducing its stake below the 5% threshold.
Key Dates
| Date | Description |
|---|---|
| 2018-09-04 | Original Schedule 13D filing date. |
| 2021-01-19 | Amendment No. 1, Amendment No. 2, and Amendment No. 3 to Schedule 13D filed. |
| 2021-06-03 | Amendment No. 4 to Schedule 13D filed. |
| 2022-09-12 | Amendment No. 5 to Schedule 13D filed. |
| 2023-11-30 | Amendment No. 6 to Schedule 13D filed. |
| 2024-05-31 | Amendment No. 7 to Schedule 13D filed. |
| 2024-08-23 | Amendment No. 8 to Schedule 13D filed. |
| 2025-01-31 | Amendment No. 9 to Schedule 13D filed. |
| 2025-06-27 | Date Vedanta Associates, L.P. ceased to be a beneficial holder of more than five percent of the Issuer's Common Stock, triggering this filing. |
| 2025-07-01 | Filing Date of Amendment No. 10 and the 'as of' date for outstanding shares. |
Keywords
Reviva Pharmaceuticals, Vedanta Associates, Vedanta Partners, Parag Saxena, Schedule 13D, Beneficial Ownership, Common Stock, SEC Filing, Shareholding, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.